BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered... Read More

HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue... Read More

HINGHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 4,000,001 shares of the Company’s common stock at a purchase price of $1.75 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition,... Read More

HINGHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 4,000,002 shares of the Company’s common stock at a purchase price of $1.75 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue... Read More

BRAINTREE, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic System, concludes 2024 with the achievement of several key milestones, including the recent FDA 510(k) submission for FDA commercial approval of LIBERTY ® , which the company believes will position the Company for continued success in 2025. “As we entered 2024, the Company had... Read More

Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live BRAINTREE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical ® Inc. (Nasdaq: MBOT), developer of the innovative single use LIBERTY ® Endovascular Robotic System, announces that its Chief Executive Officer, Harel Gadot, will be interviewed on Benzinga All Access at 10:50am ET on December 10, 2024. The live interview can be viewed at:... Read More

FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial FDA 510(k) Clearance Anticipated During the Second Quarter of 2025 Company Preparing to Commence Commercialization Following FDA 510(k) Clearance BRAINTREE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative single use LIBERTY ® Endovascular Robotic System, today announced that... Read More

U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announced that it has successfully completed enrollment and follow up for all patients in its ACCESS-PVI human... Read More

Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announced that it is currently experiencing an acceleration of patient enrollment... Read More

BRAINTREE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announced that it has successfully reached the midpoint of the ACCESS-PVI pivotal human clinical trial, enrolling and completing the follow up of 50% of the patients participating in the trial to evaluate the LIBERTY ® Endovascular Robotic Surgical... Read More

The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform The objective of Phase 2 is to develop and demonstrate new telesurgery capabilities by performing simulated interventional procedures between two facilities within the Corewell Health system BRAINTREE, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of... Read More

BRAINTREE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announces it has received ISO 13485:2016 certification for its quality management system. Receiving ISO 13485 certification indicates that a company has developed and implemented robust policies and procedures for the development and manufacture of... Read More

BRAINTREE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced it has entered into an agreement with Emory University, which will allow the parties to evaluate and explore the potential for a future collaboration in connection with autonomous robotics in endovascular procedures. Under the terms of the agreement, Emory University will assume the responsibility of exploring the... Read More

BRAINTREE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announces it has received Institutional Review Board (IRB) approval and signed a clinical trial agreement with Memorial Sloan Kettering Cancer Center, located in New York City, New York. Memorial Sloan Kettering Cancer Center will conduct the clinical... Read More

Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company’s Pivotal Human Clinical Trial. The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY ® Endovascular Robotic Surgical System. BRAINTREE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that Baptist Hospital of Miami,... Read More

The first clinical case was performed at Brigham and Women’s Hospital The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY ® Endovascular Robotic Surgical System BRAINTREE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the completion of the first procedure in a patient utilizing its LIBERTY ® Endovascular Robotic... Read More

BRAINTREE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announces it has received Institutional Review Board approval and signed a Clinical Trial Agreement with Baptist Hospital of Miami, which includes Miami Cardiac & Vascular Institute and Miami Cancer Institute. This is the second announced site that will... Read More

Following FDA Approval to Commence the Clinical Trial, an Official Site Initiation Has Taken Place as Preparation for Patient Enrollment Advances Multiple Robotic Systems Already Received by the Site to Allow Inventory Readiness in Support of Trial BRAINTREE, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced its agreement with Brigham and Women’s Hospital (BWH), a leading academic... Read More

BRAINTREE, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announces that Brigham and Women’s Hospital (BWH), a leading academic medical center located in Boston, Massachusetts, will participate as a clinical trial site for the pivotal human clinical trial as part of its Investigational Device Exemption (“IDE”) application for its LIBERTY ® Endovascular Robotic Surgical System. Dr. Dmitry... Read More

HINGHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock . In addition, in a concurrent private placement, the Company has issued... Read More

HINGHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue... Read More

BRAINTREE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announces that it has received the U.S. Food and Drug Administration’s (“FDA”) approval to proceed with its pivotal human clinical trial as part of its Investigational Device Exemption (“IDE”) application for its LIBERTY ® Endovascular Robotic Surgical... Read More

BRAINTREE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today reports that the first phase of the previously announced collaboration with Corewell Health has been completed, which demonstrated the LIBERTY® System's technical capabilities and outlines potential future applications in a range of endovascular... Read More

All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel Company Believes that Both Regulatory and Commercial Milestones to be Achieved in Accordance with the Company’s Current Timeline BRAINTREE, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY ® Endovascular Robotic Surgical System, today... Read More

BRAINTREE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY ® Endovascular Robotic Surgical System, announced that it has filed an Investigational Device Exemption (IDE) application with the US Food and Drug Administration (FDA). The IDE application follows the completion of multiple preclinical activities performed to provide preliminary safety and effectiveness... Read More

BRAINTREE, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announced it has signed a Settlement Agreement and Release with Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd. that resolves all claims asserted against the Company by these entities in a... Read More

BRAINTREE, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announced that following the recent positive results of its pivotal GLP Pre-Clinical Study, and to support its anticipated IDE submission to commence its first in human clinical trial, the Company added a US- based Clinical Research Associate (CRA). The... Read More

BRAINTREE, Mass., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 1,685,682 shares of common stock, having exercise prices ranging from $2.075 to $3.19 per... Read More

BRAINTREE, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model. As previously announced on December 7, 2023, the study... Read More

BRAINTREE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announced it has entered into a collaboration agreement with Corewell Health™. The objective of the collaboration, which will take place in multiple phases, is to enable telerobotics between remote centers by utilizing the LIBERTY Endovascular Robotic... Read More

The final histopathology and lab report supplements previous positive Company findings. The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study. BRAINTREE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announces the successful completion of its GLP... Read More

BRAINTREE, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc . (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announced the appointment of Dr. Juan Diaz-Cartelle as its new Chief Medical Officer (CMO), effective December 1, 2023. The hiring of Dr. Diaz-Cartelle, a U.S.-based physician, coincides with the transition of the Company focusing mainly on research and... Read More

BRAINTREE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Robotic Surgical System, today announces it had successfully completed the Electromagnetic Compatibility (EMC) testing section of the Verification and Validation (V&V) process. V&V are distinct procedures employed to ensure that a product, service, or system, aligns with specified requirements and... Read More

BRAINTREE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic system, today announced it had been granted a registered trademark from the US Patent and Trademark Office. The trademark “One & Done ® ” was given to the feature of the LIBERTY Robotic Surgical System which is being developed to integrate... Read More

BRAINTREE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Robotic Surgical System, today announces additional updates regarding positive outcomes of its previously announced pivotal pre-clinical study using the LIBERTY Robotic Surgical System. The pivotal study was conducted by three leading interventional radiologists that utilized the LIBERTY Robotic... Read More

The Company’s designated Notified Body confirmed dates for conducting audits for ISO 13485 certification to ensure Microbot complies with the QMS requirements of the EU MDR The Company expects that the full CE Mark approval process of obtaining clearance of sales in the European Union for the LIBERTY ® Robotic Surgical System, will be carried out in parallel with the FDA regulatory process BRAINTREE, Mass., Oct. 24, 2023... Read More

BRAINTREE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc . (Nasdaq: MBOT), developer of the innovative LIBERTY ® Robotic Surgical System, today announces that the United States District Court for the Southern District of New York, approved Microbot’s motion for summary judgment and dismissed with prejudice the previously announced Section 10(b) counterclaim brought by defendant as against Microbot in the... Read More

A total of 48 animal targets were reached with 100% usability and technical success and no visual acute intra-operative adverse events or complications This pivotal study, together with the verification and validation studies, is expected to serve as the basis for the IDE submission to the FDA BRAINTREE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ®... Read More

BRAINTREE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic system, announced today its partnership with a Contract Research Organization (CRO) in the U.S. This is an additional step in the preparations to the commencement of the Company's planned upcoming clinical trial. The CRO will provide an... Read More

BRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY ® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023. The abstract is to be presented by Professor of Interventional Radiology... Read More

BRAINTREE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc . (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic system, announces another step in its commitment to advance the commercialization processes of LIBERTY ® with the signing of a manufacturing agreement with B.Y. Medimor Ltd. The agreement governs the manufacturing of the Company's LIBERTY... Read More

HINGHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic system, today announces the expansion of its global team of experts supporting the Company as scientific advisory board members ("SAB"), with Francois H. Cornelis, MD, PhD joining Microbot's SAB. Professor Cornelis is an interventional... Read More

HINGHAM, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic system, today announced the first steps towards its planned European market clearance, by engaging with a leading Notified Body. The Notified Body will audit the Company to verify the compliance of its quality management system and the... Read More

HINGHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic surgical system, today announced that Irene Bargellini, M.D., an interventional radiologist and Chair of the Diagnostic and Interventional Radiology Department at Candiolo Cancer Institute in Turin, Italy, has joined the Company’s Scientific... Read More

HINGHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic surgical system, today announced the successful completion of an extended pre-clinical study held by leading key opinion leaders ("KOLs") at a New York-based research lab. A team of leading interventional radiologists utilized the system and... Read More

Microbot Medical Closes Fourth Registered Direct Offering Priced At-The-Market under Nasdaq Rules HINGHAM, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it closed its previously announced registered direct offering for the purchase and sale of 624,618 shares of the Company’s common stock at a purchase price of $3.25 per share of common stock priced at-the-market under... Read More

HINGHAM, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 624,618 shares of the Company’s common stock at a purchase price of $3.25 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue... Read More

HINGHAM, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic surgical system, today announced the expansion of its global IP portfolio by receiving a Grant of Protection from the Japan Patent Office for a Design Patent covering the innovative industrial design of the robotic drive of the LIBERTY... Read More

HINGHAM, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is encouraged by the continued participation and level of enthusiasm being demonstrated by the Key Opinion Leaders (KOL) globally who are using the LIBERTY ® Robotic Surgical System during the Company’s pre-clinical animal studies. Further displaying their positive experiences and satisfaction, the Company has been informed that two... Read More

HINGHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 701,756 shares of the Company’s common stock at a purchase price of $2.1375 per share of common stock priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered... Read More

HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 701,756 shares of the Company’s common stock at a purchase price of $2.1375 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue... Read More

HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic surgical system, announced it has received a grant from the Israel Innovation Authority ("IIA”) in the amount of NIS 1.62 million, which based on a recent exchange rate to the U.S. dollar, would be approximately $440,000, to further support... Read More

HINGHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular surgical robotic system, announces that an additional milestone was achieved when medical professionals experienced the Company's LIBERTY Robotic Surgical System as part of a formative study. The study was designed to enable medical professionals,... Read More

This Significant Achievement Represents Major Progression Toward Regulatory and Commercialization Paths Additional Sites in the U.S. Are Expected to Participate in the Trial HINGHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has successfully achieved another major milestone representing the next step toward the regulatory and commercial paths for the LIBERTY® Robotic... Read More

HINGHAM, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,209,500 shares of the Company’s common stock (or common stock equivalents) at a purchase price of $2.20 per share of common stock priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acted as the exclusive... Read More

HINGHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,209,500 shares of the Company’s common stock (or common stock equivalents) at a purchase price of $2.20 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to... Read More

HINGHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 655,569 shares of the Company’s common stock at a purchase price of $2.20 per share of common stock priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The... Read More

HINGHAM, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 655,569 shares of the Company’s common stock at a purchase price of $2.20 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about May 24, 2023,... Read More

HINGHAM, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Surgical Robotic System, the first single-use endovascular robotic system, today announced a highly successful extended joint pre- clinical animal study held at a leading European-based research lab. A team of six leading European interventional radiologists utilized the system and performed a total of 48... Read More

HINGHAM, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic system, today announced its Core Business Focus Program and cost restructuring plan to continue enhancing the focus on its core technology while maximizing available resources to support it. This includes the focus on completing the validation... Read More

HINGHAM, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY Robotic system, the first fully disposable endovascular robotic system, announced that it has initiated preparations for potential First-In-Human cases in Brazil, by engaging with distinguished publisher and lecturer interventional radiologist Prof. Francisco Cesar Carnevale. The engagement with Prof.... Read More

HINGHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic System, the first single-use endovascular robotic system, has received the histopathology report from the European-based MedTech research laboratory that performed the animal study for the LIBERTY Robotic System in October 2022. During the animal study, the physicians conducted 63 navigations to the... Read More

HINGHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY Robotic system, the first fully disposable robotic system, announced the system has surpassed its 100 th catheterization during multiple pre-clinical studies, with a 95% success rate of reaching pre-determined vascular targets, such as distal branches of hepatic, gastric, splenic, mesenteric, renal, hypogastric... Read More

Widely Published Interventional Radiologist Has Earned Well-Regarded Reputation Working with Prestigious Medical Centers in the U.S. and Europe The addition of Professor O’Sullivan, the Clinical Director of Radiology for the Galway Clinic in Ireland, Expands the Company’s EU Presence. HINGHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to receive global interest from... Read More

HINGHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which is rapidly scaling up its internal capabilities with globally renowned members joining its Scientific Advisory Board (SAB), today announced that Professor Mark W. Little, BSc(hons), MSc (Distinction), MBBS (Distinction), DipIPEM, FHEA, FRCR, FCIRSE, has joined the SAB, becoming the first member from the United Kingdom. Professor... Read More

HINGHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which continues to experience a rising interest in the LIBERTY ® Robotic System, the first single-use endovascular robotic system, today announced that Stavros Spiliopoulos, MD, PhD, EBIR-ES, FCIRSE, a key opinion leader (KOL) from Greece, has joined the Company’s Scientific Advisory Board (SAB). The addition of Dr. Spiliopoulos, an... Read More

HINGHAM, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic System, the first single-use endovascular robotic system, today announced that an abstract was accepted for a podium presentation at the Israeli Conference on Robotics (ICR) annual meeting, being held March 28 th in Herzliya, Israel. Dr. Eyal Morag, the Company’s Chief Medical Officer and author of... Read More

HINGHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc . (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic System, the first single-use endovascular robotic system, was recently awarded a grant from Israel’s Ministry of Economy to encourage the Company’s marketing activities and enhance the commercialization of the LIBERTY Robotic System in the US market, within the scope of its ‘Smart Money’ program.... Read More

HINGHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic System, the first single-use endovascular robotic system, announced that Harel Gadot, Chairman, CEO and President, Dr. Eyal Morag, Chief Medical Officer, and other leaders from the business team, will be attending the upcoming Society of Interventional Radiologist (SIR) annual meeting. The Company is... Read More

HINGHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), today announced that it has expanded its global presence to South America with the addition of Francisco C. Carnevale, MD, PhD, FSIR, becoming the latest key opinion leader (KOL) to join the Company’s Scientific Advisory Board (SAB). With the addition of Dr. Carnevale to its SAB, the Company now has 13 KOLs on its SAB, including seven... Read More

Allows Endovascular Procedure to be Performed from the Cath-Lab Control Room, Potentially Minimizing Radiation Exposure and Reducing Physical Strain for the Healthcare Providers Design Patent Complements Existing U.S. and European Design Patents as Feedback During Recent Meetings Continues to Support a Positive User Experience HINGHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced... Read More

Dr. Giora Weisz, a Practicing Interventional Cardiologist and Clinical Researcher who was One of the Early Users of Robotic-Enhanced Coronary Interventions, as well as Navigation and Positioning Technologies, Will be the Guest Speaker. The Webinar is Intended for All Stakeholders Interested in the Future of Endovascular Robotics, and Will be Held on Wednesday, February 8, 2023, at 1:00pm ET HINGHAM, Mass., Jan. 31, 2023... Read More

Panel of Proven Medical Device Entrepreneurs and Surgical Robotics Pioneers Will Share Their Personal Experiences of Taking Innovative New Technologies from Development to Commercialization Views on the Current and Future Endovascular Market will be Highlighted Webinar will be Held on Tuesday, January 10, 2023, at 2:00pm ET (11am PT) HINGHAM, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the... Read More

The Webinar, Which is Suitable to All Stakeholders Interested in the Future of Endovascular Robotics, Will be Held on Wednesday, December 21, 2022, at 1:00pm ET Dr. Ripal Gandhi, a Renowned Miami-Based Interventional Oncologist, Will Share His Personal Experiences Having Completed Over 100 Endovascular Robotic Surgical Procedures HINGHAM, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the... Read More

HINGHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to strengthen its intellectual property (IP) portfolio, while advancing and securing its global commercialization strategy. It has been granted a third patent in Israel for the LIBERTY ® Robotic System, covering the core capabilities of the system, such as a compact robotic device for driving movement of two or more surgical... Read More

HINGHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), in a continuation of its efforts to create barriers and expand its global intellectual property portfolio for the LIBERTY ® Robotic System, was issued a design patent allowance by the US Patent & Trademark Office (USPTO), covering the LIBERTY Robotic System’s remote controller unique interface design. “The remote controller for the... Read More

The “Access-Ability Live” by MBOT will build an online community of healthcare industry leaders who are interested in robotics to come together and share their opinion and experience First Webinar on November 16 th at 1:00 pm ET will Focus on the Evolving Endovascular Space Procedures and How Emerging New Technologies such as the LIBERTY® Robotic System may be used by Physicians in the Future HINGHAM, Mass., Nov. 15, 2022... Read More

Microbot Medical Inc. (Nasdaq: MBOT) continues to aggressively protect its global intellectual property (IP) portfolio for the LIBERTY ® Robotic System as an additional patent allowance was issued by the Israeli Patent Office, covering the modular concept, and compliments a corresponding application that was previously granted by the U.S. Patent and Trademark Office (USPTO). The allowed claims cover the unique modular and... Read More

Growing SAB Roster Includes 11 KOLs from Across the U.S., Europe, and Israel Expansion of KOL Presence and Global Centers of Excellence Continues to Accelerate the Progression of the LIBERTY ® Robotic System to Meet Future Regulatory and Commercialization Milestones Microbot Medical Inc. (Nasdaq: MBOT), which is continuing to expand its Key Opinion Leader (KOL) support network, today announced that Thierry Jacques De Baère,... Read More

Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering with a single institutional investor for the purchase and sale of 1,022,495 shares of the Company’s common stock (which includes pre-funded warrants to purchase 240,000 shares of common stock) at a purchase price of $4.89 per share of common stock (or $4.8899 per pre-funded warrant, which represents the... Read More

Microbot Medical Inc . (Nasdaq: MBOT) today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 1,022,495 shares of the Company’s common stock (which includes pre-funded warrants to purchase 240,000 shares of common stock) at a purchase price of $4.89 per share of common stock (or $4.8899 per pre-funded warrant, which represents the per share offering... Read More

Microbot Medical Inc. (Nasdaq: MBOT), announced that it has submitted the anticipated follow-up pre-submission package for the LIBERTY ® Robotic System to ensure the Company remains fully aligned with the U.S. Food and Drug Administration (FDA) as it prepares for its Investigational Device Exemption (IDE) submission and first-in-human clinical trial with the system in 2023. “We have had a positive experience with the FDA to... Read More

Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY® Robotic System, the first disposable robotic system being developed for endovascular procedures. The study was performed by a team of seasoned Key Opinion Leaders (KOLs) in the endovascular space at a world-class MedTech research laboratory with FDA-required levels of planning, controlling,... Read More

Microbot Medical Inc. (Nasdaq: MBOT) has announced that, following the recent acquisition of the endovascular assets of Nitiloop Ltd. along with other significant developments regarding the LIBERTY® Robotic System, including the commencement of its GLP animal trial, the rising interest in the LIBERTY® Robotic System by global Key Opinion Leaders (KOLs) joining its Scientific Advisory Board (SAB) and anticipated regulatory... Read More

Microbot Medical Inc. (Nasdaq: MBOT) is continuing to expand its global intellectual property portfolio for the LIBERTY ® Robotic System as a patent allowance was issued by the Israeli Patent Office, covering the LIBERTY Robotic System’s roll assembly mechanism. “Our global patent portfolio continues to expand and build continued protection of our intellectual property,” commented Harel Gadot, Chairman, CEO and President.... Read More

Integration with the LIBERTY® Robotic System & One & Done™ Technology May Enable Future Acceleration of Robotic Adoption; Represents an Additional Growth Opportunity by Accessing the $500 Million Chronic Total Occlusion (CTO) Market 1 through the Expansion of Robotic Ecosystem for Endovascular Procedures Microbot Medical Inc. (Nasdaq: MBOT) announced today, as a continuation of its recent regulatory and future... Read More

Microbot Medical Inc. (Nasdaq: MBOT), which continues to be committed to expanding its capabilities, today announced the newest appointment to its Scientific Advisory Board (SAB), David C. Madoff, M.D. Dr. Madoff, Professor of Radiology and Medical Oncology, Vice Chair for Clinical Research and Section Chief of Interventional Radiology at Yale School of Medicine, has joined the Company’s esteemed SAB. “Dr. Madoff has a... Read More

Miami-based Physician Specializes in Minimally Invasive Treatments for Peripheral Vascular Disease, Cancer, and Other Diseases Microbot Medical Inc. (Nasdaq: MBOT), continuing its recent success of strengthening its Scientific Advisory Board with the recent recruitment of Key Opinion Leaders (KOLs), today announced that Ripal T. Gandhi, MD, FSVM, will join the Company’s robust Scientific Advisory Board (SAB). Dr. Gandhi is... Read More

Microbot Medical Inc . (Nasdaq: MBOT), which continues to build a network of global leaders in the endovascular interventional space for the LIBERTY® Robotic System, today announced that Vincent Vidal, M.D., PhD, has joined its Scientific Advisory Board (SAB). Dr. Vidal is a world-leading advocate and distinguished expert of embolization techniques. He is the head of Interventional Radiology in the Imaging Department of... Read More

Microbot Medical Inc. (Nasdaq: MBOT), announced that Harel Gadot, Chairman, President and CEO, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference being held in NYC. Mr. Gadot will provide an overview of the Company and recent progress, including the commencement of the GLP pre-clinical trial, on Tuesday, September 13 th at 2:30 pm ET. The presentation will be webcast and may be accessed via... Read More

Microbot Medical Inc. (Nasdaq: MBOT) announces the commencement of its GLP Pre-Clinical Trial for the LIBERTY Robotic System at a world-class MedTech research laboratory. The study is being conducted by top Key Opinion Leaders (KOLs). “This much anticipated and important milestone represents the first step in our path to achieve regulatory approvals as we aim to transform the world of surgical robotics in general, and... Read More

A global leader in the endovascular space will collaborate with the Company as it goes through the regulatory process and future commercialization Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a reputation within the interventional radiology community for its LIBERTY ® Robotic System, today announced the newest appointment to its Scientific Advisory Board (SAB), Sebastian Flacke, M.D. The addition of this... Read More

Demonstrating another key achievement, Microbot Medical Inc. (Nasdaq: MBOT), continues to execute its objective of expanding its global intellectual property (IP) portfolio for the LIBERTY ® Robotic System as a grant for two Design Patent Applications was issued by the European Patent Office (EPO), covering the LIBERTY Robotic System’s Robotic Drive and Remote Controller. “The innovative nature of the LIBERTY Robotic System... Read More

Microbot Medical Inc. (Nasdaq: MBOT) announced, as part of the preparation for its anticipated U.S. Food and Drug Administration (FDA) and CE Mark submissions, that it recently shipped multiple LIBERTY Robotic System devices to a market-leading research laboratory to conduct the Company’s GLP pre-clinical trial. The comprehensive trial, which is anticipated to commence later this month, will be performed by a team of global... Read More

Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be presenting the Company’s Self-Cleaning Shunt (SCS) at the 16 th Asian Australasian Congress of Neurological Surgeons (AACNS). The AACNS is hosted by the Israel Neurosurgery Society and is being held from September 6 th – 8 th in Jerusalem, Israel. Dr Gustavo Rajz, Head of Pediatric Neurosurgical Unit at Shaare Zedek Medical Center, Jerusalem, will be hosting a... Read More

Microbot Medical Inc. (Nasdaq: MBOT), announced it will be presenting at the Annual Needham Virtual Healthcare Conference. Harel Gadot, Chairman, President and CEO will provide an overview of the Company and recent progress on Tuesday, April 12 th at 8:45am ET. The live and archived replays of the presentation may be accessed via the ‘Investors’ section, under ‘Presentation + Resources’ of the Company’s website at... Read More

Microbot Medical Inc. (Nasdaq: MBOT), seeking to continuously enhance its core capabilities, today announced the promotion of Rachel Vaknin as its Chief Financial Officer. Ms. Vaknin, a seasoned finance executive with 20 years of experience, joined the Company in January 2022 as VP Finance, and has replaced David Ben Naim as the Company’s CFO effective April 1, 2022. She will report directly to Harel Gadot, the Company’s... Read More

The operational momentum that Microbot Medical Inc. (Nasdaq: MBOT) experienced at the end of 2021 has continued well into the 2022 first quarter. The Company filed its pre-submission package for the LIBERTY ® Robotic System with the U.S. Food and Drug Administration (FDA), addressing the regulatory pathway for the LIBERTY ® Robotic System. This is in line with the Company’s previously stated Q1 timeline. The Company expects... Read More

Microbot Medical Inc. (Nasdaq: MBOT) announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain neurovascular procedures. “We... Read More

Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a third patent application covering the Company’s LIBERTY ® Robotic System. The Company has secured all three U.S. patents during 2021. Globally, the Company now has 47 patents issued/allowed and 26 pending patent applications and is continuously submitting applications to protect... Read More

Microbot Medical Inc. (Nasdaq: MBOT) announced that it has and will continue to implement key initiatives that will prepare the LIBERTY® Robotic System for commercialization. In conjunction with recently announced design freeze, Dr. Eyal Morag, Microbot’s Chief Medical Officer, traveled to the United States to establish a clinical infrastructure with multiple sites and leading physicians for the commencement of a human... Read More

Microbot Medical Inc. (Nasdaq: MBOT) achieved the design freeze objective for the LIBERTY® Robotic System. This milestone demonstrates the continued progress towards the commercialization of the world’s first fully disposable robotic system. The Company’s ability to reach this milestone within the previously stated timeframe reflects the tireless efforts of the Company’s engineering team, along with data compiled from the... Read More

Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second patent application covering the Company’s LIBERTY ® Robotic System. Globally, the Company now has 46 patents issued/allowed and 24 pending patent applications and is continuously submitting applications to protect its Intellectual Property. “We believe that the U.S. is the... Read More

Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance covering the Company’s LIBERTY ® Robotic System. Globally, the Company now has 45 patents issued/allowed and 24 pending patent applications. “This achievement is yet another meaningful milestone that adds a secure foundation to build our sustainable competitive advantage. This IP allows us... Read More

Microbot Medical Inc. (Nasdaq: MBOT) announced that China has become the latest global jurisdiction to issue a Notice of Allowance (NOA) for the Company’s innovative ‘One & Done’ guidewire technology, joining the European Union along with those received earlier this year from Japan and Israel. Globally, the Company now holds a total of 44 patents issued/allowed and 24 pending patent applications. “This latest patent... Read More

Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz, MD joined the Company’s Scientific Advisory Board (SAB). Dr. Weisz is a practicing interventional cardiologist and clinical researcher who has pioneered novel robotic-enhanced coronary interventions, as well as navigation and positioning technologies. His areas of expertise include cardiac... Read More

Global patent jurisdictions continue to recognize Microbot Medical Inc.’s (Nasdaq: MBOT) innovative ‘One & Done’ guidewire technology, as the Israel Intellectual Property Office has issued a Notice of Allowance (NOA). The allowed application covers Microbot’s double guidewire technology that has been granted in Europe, Japan and now Israel. Globally, Microbot Medical holds a total of 42 patents issued/allowed and 23 pending... Read More

Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent Office (JPO) that it intends to grant the Company a patent for its ‘One & Done’ guidewire technology for use with endoluminal interventions. Japan is the second jurisdiction to grant a patent for the ‘One & Done’ guidewire technology and further protects the novel technology the Company is currently developing. “We are advancing our... Read More

Microbot Medical Inc. (Nasdaq: MBOT) announced the completion of successful discussions with the U.S. Food and Drug Administration (FDA) for its Self-Cleaning Shunt (SCS). After review of the Company’s existing pre-clinical data, the FDA’s feedback will allow the Company to apply for a limited clinical investigation known as an Early Feasibility Study (EFS), which is designed for novel technologies such as the SCS.... Read More